119 related articles for article (PubMed ID: 7140004)
41. [Effects of hydration on plasma concentrations of methotrexate in patients with osteosarcoma treated with high doses of methotrexate].
Ferrari S; Orlandi M; Avella M; Caldora P; Ferraro A; Ravazzolo G; Bacci G
Minerva Med; 1992 May; 83(5):289-93. PubMed ID: 1589134
[TBL] [Abstract][Full Text] [Related]
42. Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma.
Wang YM; Sutow WW; Romsdahl MM; Perez C
Cancer Treat Rep; 1979 Mar; 63(3):405-10. PubMed ID: 284845
[TBL] [Abstract][Full Text] [Related]
43. Protein binding of methotrexate in sera from normal human beings: effect of drug concentration, pH, temperature, and storage.
Paxton JW
J Pharmacol Methods; 1981 May; 5(3):203-13. PubMed ID: 7311560
[TBL] [Abstract][Full Text] [Related]
44. Methotrexate binding to human plasma proteins.
Skibińska L; Ramlau C; Załuski J; Olejniczak B
Pol J Pharmacol Pharm; 1990; 42(2):151-7. PubMed ID: 2274472
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics in blood IV: unusual distribution, storage effect and metabolism of methotrexate.
Lee MG; Lui CY; Chen ML; Chiou WL
Int J Clin Pharmacol Ther Toxicol; 1984 Oct; 22(10):530-7. PubMed ID: 6511128
[TBL] [Abstract][Full Text] [Related]
46. Patient characteristics associated with high-risk methotrexate concentrations and toxicity.
Relling MV; Fairclough D; Ayers D; Crom WR; Rodman JH; Pui CH; Evans WE
J Clin Oncol; 1994 Aug; 12(8):1667-72. PubMed ID: 8040679
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate.
Breithaupt H; Küenzlen E
Cancer Treat Rep; 1982 Sep; 66(9):1733-41. PubMed ID: 6956440
[TBL] [Abstract][Full Text] [Related]
48. Entero-hepatic cycling of methotrexate estimated by use of the D-isomer as a reference marker.
Hendel J; Brodthagen H
Eur J Clin Pharmacol; 1984; 26(1):103-7. PubMed ID: 6714281
[TBL] [Abstract][Full Text] [Related]
49. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
Skärby T; Jönsson P; Hjorth L; Behrentz M; Björk O; Forestier E; Jarfelt M; Lönnerholm G; Höglund P
Cancer Chemother Pharmacol; 2003 Apr; 51(4):311-20. PubMed ID: 12721759
[TBL] [Abstract][Full Text] [Related]
50. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?
Glantz MJ; Cole BF; Recht L; Akerley W; Mills P; Saris S; Hochberg F; Calabresi P; Egorin MJ
J Clin Oncol; 1998 Apr; 16(4):1561-7. PubMed ID: 9552066
[TBL] [Abstract][Full Text] [Related]
51. Concentration and pH dependent steady-state volume of distribution of methotrexate estimated by a simple physiologically based method.
Lui CY; Lee MG; Chiou WL
J Pharmacokinet Biopharm; 1984 Dec; 12(6):597-610. PubMed ID: 6533295
[TBL] [Abstract][Full Text] [Related]
52. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
[TBL] [Abstract][Full Text] [Related]
54. High-dose methotrexate for osteosarcoma: toxicity and clinical results.
Breithaupt H; Küenzlen E
Oncology; 1983; 40(2):85-9. PubMed ID: 6600827
[TBL] [Abstract][Full Text] [Related]
55. Methotrexate removal during haemodialysis in a patient with advanced laryngeal carcinoma.
Thomson AH; Daly M; Knepil J; Harden P; Symonds P
Cancer Chemother Pharmacol; 1996; 38(6):566-70. PubMed ID: 8823500
[TBL] [Abstract][Full Text] [Related]
56. Methotrexate pharmacokinetics in age-fractionated erythrocytes.
Schrøder H
Cancer Chemother Pharmacol; 1986; 18(3):203-7. PubMed ID: 3467879
[TBL] [Abstract][Full Text] [Related]
57. Renal clearance of methotrexate in man during high-dose oral and intravenous infusion therapy.
Christophidis N; Louis WJ; Lucas I; Moon W; Vajda FJ
Cancer Chemother Pharmacol; 1981; 6(1):59-64. PubMed ID: 7273267
[TBL] [Abstract][Full Text] [Related]
58. Distribution of 7-hydroxymethotrexate in human blood.
Slørdal L; Sager G; Huseby NE; Aarbakke J
J Pharm Pharmacol; 1988 Jan; 40(1):50-2. PubMed ID: 2896774
[TBL] [Abstract][Full Text] [Related]
59. Pharmacologic studies on the dibutyl and gamma-monobutyl esters of methotrexate in the rhesus monkey.
Rosowsky A; Abelson HT; Beardsley GP; Ensminger WD; Kufe DW; Steele G; Modest EJ
Cancer Chemother Pharmacol; 1982 Dec; 10(1):55-61. PubMed ID: 7160046
[TBL] [Abstract][Full Text] [Related]
60. An open-label phase I pilot study of continuous intrapleural infusion of escalated doses of methotrexate in malignant pleural mesothelioma.
Ellithy MM; El Baghdady NS; El Wakeel LM; Abdeltawab KA; Badary OA
Am J Clin Oncol; 2013 Oct; 36(5):514-8. PubMed ID: 22781392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
